Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases

被引:27
作者
Gencheva, Radosveta [1 ]
Cheng, Qing [1 ]
Arner, Elias S. J. [1 ,2 ]
机构
[1] Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, S-17177 Stockholm, Sweden
[2] Natl Inst Oncol, Dept Selenoprot Res, Natl Tumor Biol Lab, H-1122 Budapest, Hungary
基金
瑞典研究理事会;
关键词
REDOX-ACTIVE DRUG; MAMMALIAN THIOREDOXIN; MOTEXAFIN GADOLINIUM; GLUTATHIONE-REDUCTASE; RHEUMATOID-ARTHRITIS; ESCHERICHIA-COLI; DOUBLE-BLIND; SCHISTOSOMA-MANSONI; PHASE-II; RECOMBINANT SELENOPROTEINS;
D O I
10.1016/j.freeradbiomed.2022.07.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human thioredoxin reductase (TrxR) is a selenoprotein with a central role in cellular redox homeostasis, utilizing a highly reactive and solvent-exposed seleno-cysteine (Sec) residue in its active site. Pharmacological modulation of TrxR can be obtained with several classes of small compounds showing different mechanisms of action, but most often dependent upon interactions with its Sec residue. The clinical implications of TrxR modulation as mediated by small compounds have been studied in diverse diseases, from rheumatoid arthritis and ischemia to cancer and parasitic infections. The possible involvement of TrxR in these diseases was in some cases serendipitously discovered, by finding that existing clinically used drugs are also TrxR inhibitors. Inhibiting isoforms of human TrxR is, however, not the only strategy for human disease treatment, as some pathogenic parasites also depend upon Sec-containing TrxR variants, including S. mansoni, B. malayi or O. volvulus. Inhibiting parasite TrxR has been shown to selectively kill parasites and can thus become a promising treatment strategy, especially in the context of quickly emerging resistance towards other drugs. Here we have summarized the basis for the targeting of selenoprotein TrxR variants with small molecules for therapeutic purposes in different human disease contexts. We discuss how Sec engagement appears to be an indispensable part of treatment efficacy and how some therapeutically promising compounds have been evaluated in preclinical or clinical studies. Several research questions remain before a wider application of selenoprotein TrxR inhibition as a first-line treatment strategy might be developed. These include further mechanistic studies of downstream effects that may mediate treatment efficacy, identification of isoform-specific enzyme inhibition patterns for some given therapeutic compounds, and the further elucidation of cell-specific effects in disease contexts such as in the tumor microenvironment or in host-parasite interactions, and which of these effects may be dependent upon the specific targeting of Sec in distinct TrxR isoforms.
引用
收藏
页码:320 / 338
页数:19
相关论文
共 43 条
  • [21] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration
    Andreas, Kristin
    Haeupl, Thomas
    Luebke, Carsten
    Ringe, Jochen
    Morawietz, Lars
    Wachtel, Anja
    Sittinger, Michael
    Kaps, Christian
    [J]. ARTHRITIS RESEARCH & THERAPY, 2009, 11 (01)
  • [22] Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
    Biswas, Raju
    Ghosh, Dipanjana
    Dutta, Bhramar
    Halder, Urmi
    Goswami, Prittam
    Bandopadhyay, Rajib
    [J]. CURRENT GENE THERAPY, 2021, 21 (03) : 207 - 215
  • [23] Efficacy of berberine in treatment of rheumatoid arthritis: From multiple targets to therapeutic potential
    Huang, Dan-na
    Wu, Fang-fang
    Zhang, Ai-hua
    Sun, Hui
    Wang, Xi-jun
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 169
  • [24] Occurrence of a conserved domain in ATP diphosphohydrolases from pathogenic organisms associated to antigenicity in human parasitic diseases
    Ribeiro Gomes Maia, Ana Carolina
    Detoni, Michelle Lima
    Porcino, Gabriane Nascimento
    Soares, Thais Vieira
    do Nascimento Gusmao, Michelia Antonia
    Fessel, Melissa Regina
    Marques, Marcos Jose
    Souza, Maria Aparecida
    Zech Coelho, Paulo Marcos
    Silva Gomes Estanislau, Juliana Assis
    da Costa Rocha, Manoel Otavio
    Santos, Marcelo de Oliveira
    Faria-Pinto, Priscila
    Vasconcelos, Eveline Gomes
    [J]. DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2011, 35 (10) : 1057 - 1065
  • [25] Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
    Du, Jintong
    Qiao, Yu
    Sun, Lele
    Wang, Xiuwen
    [J]. CURRENT DRUG TARGETS, 2014, 15 (03) : 335 - 346
  • [26] Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization study
    Cao, Yu
    Yang, Ying
    Hu, Qingfeng
    Wei, Guojun
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [27] Identification of potential drug targets for rheumatoid arthritis from genetic insights: a Mendelian randomization study
    Yu Cao
    Ying Yang
    Qingfeng Hu
    Guojun Wei
    [J]. Journal of Translational Medicine, 21
  • [28] Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases
    Gage, Meghan C.
    Thippeswamy, Thimmasettappa
    [J]. CNS DRUGS, 2021, 35 (01) : 1 - 20
  • [29] Exploring new drug treatment targets for immune related bone diseases using a multi omics joint analysis strategy
    Yang, Wei
    Liu, Chenglin
    Li, Zhenhua
    Cui, Miao
    [J]. SCIENTIFIC REPORTS, 2025, 15 (01):
  • [30] PI3K isoforms as drug targets in inflammatory diseases: Lessons from pharmacological and genetic strategies
    Harris, Stephanie J.
    Foster, John G.
    Ward, Stephen G.
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (11) : 1151 - 1162